A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at the University of Pittsburgh School of Public Health and the Pennsylvania State University. The study was published today in npj Vaccines.
New mRNA vaccine is more effective and less costly to develop, study finds
